GLP-2
Recent research & studies
- Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO…
- Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.
Context: Weight management is key to managing polycystic ovary syndrome (PCOS) and overweight/obesity but is challenging for many. Evidence regarding tirzepatide's efficacy in women with polycystic ovary syndrome is limited. Objectives: To quantify the effectiveness of tirzepatide for weight loss…
- Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this…
- Avexitide for Treatment of Post-Bariatric Hypoglycemia
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by…
- Efficacy of a Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use: A Clinical, Subjective, and Trichogram Evaluation
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days. Researchers will evaluate hair loss, hair density, and hair growth through…
- Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient outcomes. In this study patients with non-small cell lung cancer…
- Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists have transformed the pharmacological management of type 2 diabetes (T2D) and obesity, yet substantial interindividual variability in treatment response remains a defining clinical challenge. Methods: Narrative review. PubMed was…
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a…
- Venous Congestion in Metabolic Heart Disease: Potential Indirect Role of Dual Incretin Agonists.
Introduction: Venous congestion is responsible for symptoms, organ dysfunction, and negative outcomes in heart failure. In obesity-related Heart Failure (HF) with preserved ejection fraction (HFpEF), metabolic dysfunction, inflammation, endothelial damage, and sodium retention might exacerbate venous congestion. Method: This structured…
- Severe Dumping and Persistent Obesity in a Post-Roux-en-Y Gastric Bypass Patient With a Non-discernible Gastric Pouch and Symptomatic Improvement on Tirzepatide: A Case Report.
Rapid transit of ingested nutrients into the small bowel following gastric or esophageal surgery can trigger dumping syndrome, a recognized postoperative complication seen with particular frequency after Roux-en-Y gastric bypass (RYGB). Under normal operative conditions, RYGB constructs a proximal gastric…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
